Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. - Wikidata - wikimedia - TriplyDB

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

http://www.wikidata.org/entity/Q34815786

about

Bortezomib for the treatment of multiple myeloma Current Trends of Renal Impairment in Multiple Myeloma First line vs delayed transplantation in myeloma: Certainties and controversies Multiple myeloma in the very elderly patient: challenges and solutions Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis Novel strategies to target the ubiquitin proteasome system in multiple myeloma Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Many multiple myelomas: making more of the molecular mayhem Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy Small molecules in the treatment of systemic lupus erythematosus Advances in the autologous and allogeneic transplantation strategies for multiple myeloma Molecular pathogenesis of multiple myeloma: basic and clinical updates Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies New criteria for response assessment: role of minimal residual disease in multiple myeloma Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.The Danish National Multiple Myeloma Registry Touch and go: nuclear proteolysis in the regulation of metabolic genes and cancer Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy Recent advances in multiple myeloma: a Korean perspective Cost-effectiveness of bortezomib for multiple myeloma: a systematic review Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma Clinical use of proteasome inhibitors in the treatment of multiple myeloma Novel therapeutic strategies for multiple myeloma Trial Watch: Proteasomal inhibitors for anticancer therapy Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo Evolving Therapies and FAK Inhibitors for the Treatment of Cancer Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Malfolded protein structure and proteostasis in lung diseases.Older patients with myeloma derive similar benefit from autologous transplantation.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.

P2860

Q24185881-8A9D2CA7-917A-4507-80BA-F270D8133062 Q26740444-9BDC7A3E-2921-4278-AB3D-ABEB8EEB4ADD Q26745957-93521B50-DE5C-4E20-8C60-A774BA5ABD7D Q26752991-06CF224C-71EE-4865-B4F3-4E3E0ACAEB01 Q26766718-2D457960-3148-491A-BB0D-63E0AA2D9002 Q26767418-00E0F05C-0B96-4090-B347-272D9A158C1F Q26773246-52859B7A-D4FF-4AE6-89C9-07DD6D2E7029 Q26774897-9799F295-A79B-4109-A36A-ED684B9CA68D Q26822754-EF583980-06DD-4830-B64D-3A25F1B86D46 Q26852892-D1098A51-2F15-479B-97E3-5288FF9788B8 Q26998884-CCDB84C5-05CC-48C6-AE1D-B115AD76F471 Q27002668-0B38FAD6-DFD8-4E86-8015-9993F3064251 Q27003218-32B26DAB-99B3-4E5F-A1EE-2808CAA41C5C Q27010090-B4046849-0D16-4E3C-811F-6CD0C378DD28 Q27014801-9A786D71-4138-4E2F-A097-8A75FC31652A Q27026205-2160EC30-5F06-416B-8C49-D7E13D5A6315 Q27026478-6F17FCBC-25AC-42D3-80DA-787ACEC8A5B1 Q27027512-89267842-68DF-4720-B92A-C91B05A6EAEE Q27316833-DC8A46E9-7724-4EDF-B3D5-F2DC88E45122 Q27663486-5A1B233A-EBDE-47E9-BE98-2A5910C5BBF6 Q27677425-83D58E8D-B603-492F-90D0-E014542E27B8 Q27692033-FA468CE0-8D36-4907-B23B-55AE50C87CDC Q28067187-9B73AD97-FCD9-4211-A6BF-30FFF52E3108 Q28068146-FF6A5569-D544-4855-9E23-7BB350EAD669 Q28070090-668FDB7C-2018-44EF-BA00-AD2ABC67C741 Q28074521-2AA6A8D5-8EC6-4862-8505-0F0AD2AF93D7 Q28075297-40ED787B-674F-433E-8887-2157AAC8B42B Q28076147-B418C200-3B01-4E35-A08E-D0E867343B4F Q28076646-22B50C4B-F21B-4F35-A4B1-49B727C3C92E Q28080823-3BDA10BA-542E-4EC0-8449-8454D408FE96 Q28080999-C552E537-F687-4288-BA84-4DBA904BA270 Q28081590-AD86897E-27C6-4CDD-85CB-4035E5379BE6 Q28082910-532A4725-497F-42AC-B4E9-37216F21492A Q28084683-5FE3000C-48F1-4FA4-AB59-89B0B5EFAC9B Q28483760-0CDA683E-5368-410B-A30A-FD606419D189 Q28972291-E0188D54-67D7-40A4-BA9E-989F9855FF42 Q30249513-3BD059F5-1BC8-48A2-9C8A-ED6AFE892E4B Q30353585-2153594F-DF23-40D4-8BD0-0E328C57C315 Q30370038-23124882-430E-44B5-A5F5-976EF59EF6B0 Q30424188-660EA40E-DDA5-47E8-A141-7FAF47DD7DEB

P2860

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

http://www.wikidata.org/entity/Q34815786

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@ast

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@en

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@nl

type

label

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@ast

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@en

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@nl

prefLabel

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@ast

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@en

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@nl

P1433

Q34815786-BE055C30-112C-454B-BD34-E1B723B8E3AF

P1476

Q34815786-0C6E156F-2C9D-43C3-A3E5-8DDCE9EAA4F7

P2093

Q34815786-07B9AA04-62E5-4EE7-A232-B9868A9CD7EC

Q34815786-0F9DAEA0-4E88-43FA-AE33-1CD7F0DBF3DB

Q34815786-111C39E1-BE4D-4DED-AC76-099F4A9DAC2A

Q34815786-200C6433-08E3-437B-AE2E-378D222353C4

Q34815786-23DD97F4-B5DE-4556-92CD-1060D6C1EFC0

Q34815786-540F7FA1-035B-4A8F-9DA4-C5BD8FC247B0

Q34815786-565D274F-49F4-4D1C-B7D6-F8D6C54E5FF5

Q34815786-5D869A9B-A9D1-4743-9847-5E0F7D4ADEEA

Q34815786-5E351852-62BF-4FA0-AB8E-AEBA13DD4BE1

Q34815786-75E168A6-C9B9-48BE-A28C-E812262E2CB9

P304

Q34815786-A6EA5F02-0F03-4264-B54B-C1432B80E8DD

P31

Q34815786-C8CFADD9-F065-4F64-9F25-202335B4256E

P356

Q34815786-E3003FD9-B864-49E0-8752-5C0DD44699DD

P407

Q34815786-EACC861B-F076-4004-9939-2670D1F4F2C4

P433

Q34815786-52B761D3-842D-44AF-80C2-55C3B47DF617

P478

Q34815786-CE99CB37-5493-4C02-9CAD-3A64FBE5E151

P50

Q34815786-2C5E7589-C411-4583-8C8E-DA19050E45A3

Q34815786-3B162B7C-EC51-4518-A514-B366EFDF8284

Q34815786-3D63B253-C6A5-4ADA-B04F-41BE7F4681AF

Q34815786-BE7DABC3-AF0E-4784-A6DE-F27C2831F596

Q34815786-C60F86C3-C273-44D7-8C27-ED35DCBCE299

Q34815786-E236CC3E-E072-4FFE-8304-AB4AD7157632

Q34815786-F70E0FFF-3636-4CD8-9594-55D8A4BAE129

P577

Q34815786-70E5BF59-56C0-44AF-B2F2-55EC2A1B2B83

P698

Q34815786-9A16B654-8A2F-435C-B8FE-EED036E7D65F

P356

P1433

The New England Journal of Medicine

P1476

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@en

P2093

Andrew Cakana

http://www.w3.org/2001/XMLSchema#string

Bin Jiang

http://www.w3.org/2001/XMLSchema#string

Dixie L Esseltine

http://www.w3.org/2001/XMLSchema#string

Helgi van de Velde

http://www.w3.org/2001/XMLSchema#string

Jesús F San Miguel

http://www.w3.org/2001/XMLSchema#string

Kevin Liu

http://www.w3.org/2001/XMLSchema#string

Maria T Petrucci

http://www.w3.org/2001/XMLSchema#string

Maria-Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

Martin Kropff

http://www.w3.org/2001/XMLSchema#string

Nuriet K Khuageva

http://www.w3.org/2001/XMLSchema#string

P304

906-917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0801479

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Anna Dmoszyńska

Kudrat M Abdulkadyrov

Kenneth C Anderson

Antonio Palumbo

Paul G Richardson

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18753647

http://www.w3.org/2001/XMLSchema#string